COYA
Coya Completes Enrollment Phase 2/3 ALS Trial
Coya Therapeutics finished enrolling its Phase 2/3 ALSTARS trial and announced plans for an open-label extension. The company reported $35.8 million in cash as of September 30, 2026.
COYA news
Latest 1 stories · newest Nov 10, 2026
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same COYA feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/COYA/newsSTART FREE